AACR 2023 Highlights: CAR-T Therapies and Monoclonal Antibody Combinations in Cancer Research
The 2023 edition of the American Association for Cancer Research (AACR) annual meeting has concluded,...
TPD
Haisco Pharmaceutical Gets CDE Approval for HSK38008 Prostate Cancer Clinical Study
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving approval from the Center for...
Haisco Pharmaceutical’s EGFR-PROTAC HSK40118 Gains NMPA Approval for Clinical Trials
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received clinical...
Accutar Biotech Begins Phase I Trial for AC0176 in China
New Jersey-based Accutar Biotechnology Inc., which is heavily backed by Chinese funds, has announced the...
CDE Accepts Clinical Trial Filing for Ranok’s First-in-Class BRD4 Degradation Drug RNK05047
The Center for Drug Evaluation (CDE) website indicates that a clinical trial filing for RNK05047,...
Kintor’s GT20029 Shows Positive Results in US Phase I Study for AGA and Acne
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced positive topline data from a Phase I...
Haisco’s Prostate Cancer Drug HSK38008 and DPP-4 Inhibitor HSK7653 Accepted for Review
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that the clinical trial filing for...
BeiGene Outlines Global R&D Strategy at J.P. Morgan Healthcare Summit
China-based biotech BeiGene (Nasdaq: BGNE, HKG: 6160) provided an update on its company strategy and...
Haisco’s EGFR-PROTAC HSK40118 Accepted for Review by China’s NMPA
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its clinical trial filing...
Hinova’s PROTAC Drug HP518 Accepted for FDA Review in mCRPC
China-based biopharma Hinova Pharmaceuticals has announced that a clinical trial filing for its androgen receptor...
Shaanxi Panlong Receives Patents for Coronavirus 3CL Protease Inhibitor
China-based Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864) has announced receiving two patents (US11518759B1,...
Hangzhou Polymed Biopharmaceuticals Raises Funds for Clinical Pipeline
China-based Hangzhou Polymed Biopharmaceuticals has reportedly completed a Pre-Series A+ financing round, raising an undisclosed...
Kintor Pharma’s GT20029 Shows Positive Results in Phase I Study for Androgenetic Alopecia and Acne
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced positive results from a Phase I clinical...
Kintor Completes Enrollment for GT20029 Phase I Study in US
China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced the completion of enrollment for a Phase I...
Kintor’s Dual c-Myc/GSPT1 Degradation Therapy GT19715 Shows Promise in Pre-Clinical Studies
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has published positive results from a pre-clinical study of...
Accutar Biotechnology Initiates Phase I Trial for ERα Targeting Degradation Molecule AC0682
New Jersey-based Accutar Biotechnology Inc., which is heavily backed by Chinese funds, has announced the...
Gluetacs Therapeutics Files IND for Molecular Glue Degrading Agent in China
Gluetacs Therapeutics has reported filing an Investigational New Drug (IND) application for its first molecular...
U Protech Secures Angel Financing for PROTAC and Molecular Glue Drug Pipeline
U Protech, a Hangzhou-based biotech focused on next-generation protein degradation therapies, has raised tens of...
Ranok Therapeutics Doses First Patient in RNK05047 Study for BRD4-Targeted Cancers
Ranok Therapeutics Co., Ltd, a Hangzhou-based biotech firm, announced that the first patient has been...
Kintor Pharma Completes GT20029 Phase I Study for Hair Loss and Acne
China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced the completion of dosing all 92 subjects in...